<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CACNA1B — Calcium Voltage-Gated Channel Subunit Alpha1 B</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CACNA1B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Calcium Voltage-Gated Channel Subunit Alpha1 B</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>9q34.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/785" target="_blank">785</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148438" target="_blank">ENSG00000148438</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/601314" target="_blank">601314</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q00962" target="_blank">Q00962</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Epilepsy](/diseases/epilepsy), [ALS](/diseases/als), Neurodevelopmental Disorders</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (neurons), Spinal cord, Peripheral nervous system</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Pathways</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">Calcium Signaling, Synaptic Transmission, Neuronal Excitability</td>
</tr>
<tr>
<td class="label">Associated Diseases</
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">CACNA1B — Calcium Voltage-Gated Channel Subunit Alpha1 B</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>CACNA1B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Calcium Voltage-Gated Channel Subunit Alpha1 B</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>9q34.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/785" target="_blank">785</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000148438" target="_blank">ENSG00000148438</a></td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://omim.org/entry/601314" target="_blank">601314</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q00962" target="_blank">Q00962</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Parkinson's Disease](/diseases/parkinsons-disease), [Epilepsy](/diseases/epilepsy), [ALS](/diseases/als), Neurodevelopmental Disorders</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (neurons), Spinal cord, Peripheral nervous system</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Pathways</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">Calcium Signaling, Synaptic Transmission, Neuronal Excitability</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">87 edges</a></td>
</tr>
</table>
CACNA1B (Calcium Voltage-Gated Channel Subunit Alpha1 B) encodes the pore-forming α1B subunit of voltage-gated N-type calcium channels (Cav2.2). These channels are critical regulators of neuronal excitability, neurotransmitter release, and synaptic plasticity. CACNA1B is expressed predominantly in the central and peripheral nervous systems where it mediates rapid synaptic transmission and modulates neuronal signaling pathways implicated in neurodegenerative diseases[@ertel2000].
N-type calcium channels are members of the high-voltage-activated calcium channel family that require strong depolarization for activation. The CACNA1B subunit forms the channel's central pore and determines its pharmacological and biophysical properties. These channels are strategically positioned at presynaptic terminals where they couple membrane depolarization to neurotransmitter release, making them essential for normal synaptic function[@catterall2011].
The importance of CACNA1B in neurological function is underscored by its involvement in multiple disorders including Parkinson's disease, epilepsy, amyotrophic lateral sclerosis (ALS), and various neurodevelopmental conditions. Genetic variants in CACNA1B have been associated with disease susceptibility and progression, while pharmacological targeting of N-type channels has proven therapeutic value.
The CACNA1B gene is located on chromosome 9q34.3 and spans approximately 90 kb of genomic DNA. The gene consists of 47 exons that encode a protein of approximately 2339 amino acids. The genomic organization follows the characteristic pattern of voltage-gated calcium channel α1 subunits, with each transmembrane segment encoded by separate exons facilitating alternative splicing[@lipscombe2003].
Multiple splice variants of CACNA1B generate channels with distinct properties. Exon 21 splice variants affect channel trafficking and surface expression, while exon 31 variants modify kinetic properties and voltage dependence. C-terminal variants influence interaction with accessory proteins and regulatory pathways. Alternative splicing produces N-type channels with varying properties that match the functional requirements of different neuronal populations. This diversity enables precise tuning of calcium signaling throughout the nervous system.
The regulatory control of alternative splicing adds another layer of complexity to CACNA1B function. Neuronal activity and various signaling pathways can modulate splice site selection, providing a mechanism for rapid adjustment of channel properties in response to changes in neuronal activity.
The CACNA1B promoter contains several regulatory elements that enable precise control of expression. cAMP response elements (CRE) allow transcriptional regulation by neuronal activity through the CREB family of transcription factors. NF-κB binding sites enable inflammation-responsive expression, linking channel levels to immune status. Neuron-specific enhancers direct expression to appropriate neuronal populations, while activity-dependent elements support input-specific regulation.
The promoter also contains binding sites for RE1-silencing transcription factor (REST), which represses CACNA1B in non-neuronal cells. This repression is removed during neuronal development, enabling neuron-specific expression.
The CACNA1B protein (Cav2.2) is the largest subunit of voltage-gated calcium channels and determines the channel's core properties.
The α1B subunit contains four homologous domains (I-IV), each with six transmembrane segments (S1-S6). The S4 segments contain positively charged residues that sense membrane voltage, while the S5-S6 segments form the channel's pore. The intracellular loops between domains contain binding sites for regulatory proteins and channel modulators[@yu2003].
The N-terminus contains regulatory domains that influence channel trafficking and localization. This region interacts with synaptic scaffold proteins that position channels at presynaptic active zones. The C-terminus interacts with multiple regulatory proteins including calmodulin, G-protein βγ subunits, and scaffold proteins that localize channels to presynaptic terminals.
The cytoplasmic loops between domains are sites for post-translational modifications and protein-protein interactions. Phosphorylation by various kinases modulates channel activity, while binding of accessory proteins regulates trafficking and localization.
N-type calcium channels exhibit several characteristic properties. Voltage dependence requires strong depolarization with a threshold around -20 mV. Inactivation occurs through rapid voltage-dependent mechanisms combined with calcium-dependent processes. The channel has high single-channel conductance for calcium ions and is sensitive to blocking by ω-conotoxin GVIA and other peptide toxins.
The biophysical properties of CACNA1B channels can be modulated by auxiliary subunits. The β subunit modulates voltage dependence and kinetics, while the α2δ subunit affects trafficking and expression levels.
CACNA1B channels are predominantly localized to presynaptic nerve terminals where they trigger neurotransmitter release. They are also found in dendritic shafts where they modulate synaptic integration, somatic membranes where they control neuronal excitability, and axon initial segments where they regulate action potential initiation.
This strategic localization enables CACNA1B to function at multiple points in neuronal signaling, from dendritic input integration to synaptic output.
N-type calcium channels play essential roles in neuronal physiology through their control of calcium influx at critical cellular locations.
The primary function of CACNA1B channels is coupling action potential arrival at presynaptic terminals to neurotransmitter release[@tedford2006]. When an action potential invades the terminal, N-type channels open rapidly, allowing calcium influx that triggers synaptic vesicle fusion through the SNARE complex machinery.
This coupling is particularly important for fast synaptic transmission, particularly at excitatory synapses, and for synchronous release that ensures precise temporal coordination. N-type channels also contribute to synaptic depression during high-frequency stimulation and modulate short-term plasticity by affecting release probability.
The efficiency of this coupling is highly regulated by various presynaptic mechanisms including vesicle pool size, calcium buffer capacity, and the precise localization of channels relative to release sites.
Beyond synaptic transmission, CACNA1B channels modulate neuronal excitability through several mechanisms. Dendritic calcium influx through these channels influences dendritic integration and synaptic plasticity. Back-propagating action potentials that invade dendrites contribute to calcium signaling, while CACNA1B-mediated currents affect intrinsic plasticity and ion channel modulation.
The contribution of N-type channels to neuronal excitability varies across different neuronal populations, reflecting the diverse roles these channels play in neural circuit function.
Calcium entry through CACNA1B channels activates several intracellular signaling pathways. Calmodulin activation triggers calcium-dependent inactivation, providing a feedback mechanism for channel regulation. Kinase cascades including CaMKII and PKC are activated by calcium entry, affecting synaptic plasticity and other neuronal functions. Gene expression is modulated through calcium-dependent transcription factors, while cytoskeletal remodeling occurs via calcium-activated proteases.
CACNA1B has emerged as an important player in Parkinson's disease pathogenesis through effects on dopaminergic neuron survival, synaptic function, and disease progression[@surmeier2010].
N-type calcium channels contribute to the unique vulnerability of dopaminergic neurons in the substantia nigra pars compacta (SNc). These neurons exhibit pacemaker-like activity that relies heavily on L-type calcium channels, but N-type channels also play a role in regulating their excitability and calcium homeostasis.
The constant calcium influx through these channels creates metabolic stress that makes dopaminergic neurons particularly susceptible to mitochondrial dysfunction and oxidative damage. This vulnerability is compounded in PD by additional calcium dysregulation and mitochondrial impairments. The interplay between calcium handling and mitochondrial function is particularly important in these neurons.
In Parkinson's disease, CACNA1B dysfunction contributes to synaptic failure in several ways. Altered release probability due to changes in presynaptic calcium entry affects neurotransmitter release. Synaptic vesicle depletion results from impaired replenishment of releasable vesicle pools. Aberrant plasticity manifests as abnormal short-term and long-term plasticity. Dopamine handling is impaired through dysregulated regulation of dopamine release and reuptake.
N-type calcium channels represent a therapeutic target in PD. Ziconotide, the N-type channel blocker, has been investigated for PD treatment, though its psychotomimetic effects limit clinical utility. Novel blockers with better pharmacological profiles are in development. Potential neuroprotective effects through disease modification are being explored.
Genetic variants in CACNA1B have been associated with PD risk. Single nucleotide polymorphisms affect channel expression or function. Expression quantitative trait loci influence CACNA1B levels in brain tissue. Functional variants may alter disease progression.
CACNA1B contributes to motor neuron degeneration in ALS through multiple mechanisms[@van2006].
Motor neurons are particularly susceptible to excitotoxic cell death, and CACNA1B channels contribute to this vulnerability. Calcium overload occurs through excessive calcium entry via N-type channels. Synergistic effects with glutamate amplify excitotoxic damage. Impaired calcium buffering reduces capacity to handle calcium loads, while downstream protease activation triggers cell death pathways.
ALS involves early synaptic dysfunction that precedes motor neuron death. Neuromuscular junction denervation occurs through impaired presynaptic function. Excessive neurotransmitter release may contribute to toxicity. Synaptic stripping by reactive microglia removes synapses.
N-type calcium channel blockers have been explored in ALS. Ziconotide effects in preclinical studies show some benefit, while combination approaches with glutamate antagonists may provide enhanced benefit. Neuroprotection is achieved by reducing calcium-mediated cell death.
CACNA1B variants are associated with epilepsy syndromes through effects on neuronal excitability and synaptic transmission[@zamponi2015].
Mutations in CACNA1B cause or contribute to epilepsy. Gain-of-function mutations increase channel activity and neuronal excitability, potentially leading to hyperexcitability. Loss-of-function variants may cause compensatory changes affecting excitability in different ways. Developmental effects may alter circuit formation during development.
N-type calcium channel blockers are used in epilepsy treatment. Some antiepileptic drugs target N-type channels. The mechanism involves reducing excessive neuronal calcium entry. Side effects limit utility due to the ubiquitous channel distribution.
Several compounds target N-type calcium channels. Ziconotide, a peptide toxin from cone snail, is highly selective but produces psychotomimetic effects. ω-Conotoxins serve as research tools and therapeutic candidates. Small molecule blockers represent drug development candidates.
Current development focuses on blood-brain barrier penetration to improve CNS availability, isoform selectivity to target specific channel subtypes, state-dependent block to reduce toxicity, and disease-modified approaches for neuroprotection.
Active research areas include genetic therapies using antisense oligonucleotides for gain-of-function mutations, channel modulators including positive and negative allosteric modulators, and combination therapies for multi-target approaches in complex diseases.
CACNA1B knockout mice exhibit embryonic lethality, demonstrating the essential nature of this channel. Conditional knockouts enable study in specific neuronal populations. Transgenic lines with fluorescently tagged channels allow visualization of channel localization.
Several models investigate CACNA1B in disease contexts. Parkinson's models using neurotoxins show CACNA1B involvement. Epilepsy models demonstrate seizure susceptibility from channel mutations. ALS models reveal motor neuron vulnerability.
Understanding CACNA1B function in neurodegeneration continues to evolve. Key questions remain about the precise mechanisms of channel dysfunction in different diseases and how genetic variation contributes to disease risk.
Emerging technologies including single-cell transcriptomics and proteomics will provide insights into cell-type specific CACNA1B function. CRISPR-based approaches enable precise genetic manipulation to test causality.
The following diagram shows the key molecular relationships involving CACNA1B Gene discovered through SciDEX knowledge graph analysis: